U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT06897930) titled 'A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE' on March 12.
Brief Summary: This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus Erythematosus.
Study Start Date: March 25
Study Type: INTERVENTIONAL
Condition:
Lupus Erythematosus, Systemic
Intervention:
BIOLOGICAL: AZD0120
Single infusion of AZD0120 on visit DAY 1 after completing required lymphodepleting chemotherapy..
DRUG: Cyclophosphamide
Lymp...